| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jonathan M Meyer, Michael A Cummings, George Procto. Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review. CNS spectrums. vol 22. issue 5. 2019-07-02. PMID:28004621. |
among the adjunctive and augmentation strategies, certain second-generation antipsychotics (sgas) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. |
2019-07-02 |
2023-08-13 |
Not clear |
| Brent P Forester, Martha Sajatovic, Joyce Tsai, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 26. issue 2. 2019-06-28. PMID:29146409. |
safety and effectiveness of long-term treatment with lurasidone in older adults with bipolar depression: post-hoc analysis of a 6-month, open-label study. |
2019-06-28 |
2023-08-13 |
Not clear |
| Brent P Forester, Martha Sajatovic, Joyce Tsai, Andrei Pikalov, Josephine Cucchiaro, Antony Loebe. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 26. issue 2. 2019-06-28. PMID:29146409. |
to evaluate the safety and effectiveness of 6 months of treatment with lurasidone in older adults with a diagnosis of bipolar i depression. |
2019-06-28 |
2023-08-13 |
Not clear |
| Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter, Antony Loebe. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 19. issue 8. 2019-04-26. PMID:28264635. |
lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. |
2019-04-26 |
2023-08-13 |
Not clear |
| Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, David J Bond, Benicio N Frey, Verinder Sharma, Benjamin I Goldstein, Soham Rej, Serge Beaulieu, Martin Alda, Glenda MacQueen, Roumen V Milev, Arun Ravindran, Claire O'Donovan, Diane McIntosh, Raymond W Lam, Gustavo Vazquez, Flavio Kapczinski, Roger S McIntyre, Jan Kozicky, Shigenobu Kanba, Beny Lafer, Trisha Suppes, Joseph R Calabrese, Eduard Vieta, Gin Malhi, Robert M Post, Michael Ber. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders. vol 20. issue 2. 2019-01-25. PMID:29536616. |
first-line options for bipolar i depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. |
2019-01-25 |
2023-08-13 |
Not clear |
| Nicolas A Nuñez, Gabriella Gobb. Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression: A Case Report Study. Journal of clinical psychopharmacology. vol 37. issue 2. 2019-01-07. PMID:28129315. |
lurasidone and mood stabilizers in treatment-resistant unipolar depression: a case report study. |
2019-01-07 |
2023-08-13 |
Not clear |
| Akshya Vasudev, Sumit Chaudhari, Rickinder Sethi, Rachel Fu, Rachel M Sandieson, Brent P Foreste. A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients. Drugs & aging. vol 35. issue 10. 2018-12-11. PMID:30187288. |
we conducted a systematic search utilizing the medline, embase, psycinfo and cochrane library electronic databases, with the aim of identifying all rcts comparing newer atypical antipsychotics approved by the us fda since 2002 (including brexpiprazole, cariprazine, lurasidone, iloperidone, asenapine, paliperidone, and aripiprazole) with placebo or another comparator, in the treatment of any phase of bipolar disorder (including mania, depression or mixed episodes while used as an acute or maintenance treatment) in older adults (> 65 years). |
2018-12-11 |
2023-08-13 |
Not clear |
| Marta Kot, Anna Haduch, Mariusz Papp, Władysława A Danie. The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression. Drug metabolism and disposition: the biological fate of chemicals. vol 45. issue 12. 2018-07-20. PMID:28935656. |
the effect of chronic treatment with lurasidone on rat liver cytochrome p450 expression and activity in the chronic mild stress model of depression. |
2018-07-20 |
2023-08-13 |
rat |
| Marta Kot, Anna Haduch, Mariusz Papp, Władysława A Danie. The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression. Drug metabolism and disposition: the biological fate of chemicals. vol 45. issue 12. 2018-07-20. PMID:28935656. |
the aim of our present research was to determine the effect of the novel atypical neuroleptic drug with antidepressant properties lurasidone, on the expression (mrna and protein level) and activity of liver cyp isoforms involved in the metabolism of drugs and endogenous steroids, in the chronic mild stress (cms) model of depression. |
2018-07-20 |
2023-08-13 |
rat |
| Martin J Lan, Harry Rubin-Falcone, Fatima Motiwala, Ying Chen, Jonathan W Stewart, David J Hellerstein, J John Mann, Patrick J McGrat. White matter tract integrity is associated with antidepressant response to lurasidone in bipolar depression. Bipolar disorders. vol 19. issue 6. 2018-05-10. PMID:28796415. |
white matter tract integrity is associated with antidepressant response to lurasidone in bipolar depression. |
2018-05-10 |
2023-08-13 |
Not clear |
| Joseph R Calabrese, Andrei Pikalov, Caroline Streicher, Josephine Cucchiaro, Yongcai Mao, Antony Loebe. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 27. issue 9. 2018-05-02. PMID:28689688. |
probability of recurrence on lurasidone was significantly lower in patients with an index episode of depression (hr, 0.57; p=0.039), in patients with any index episode who were not rapid-cycling (hr, 0.69; p=0.046), and when recurrence was based on madrs, ymrs, or cgi-bp-s severity criteria (hr, 0.53; p=0.025; sensitivity analysis). |
2018-05-02 |
2023-08-13 |
Not clear |
| Michele Fornaro, Domenico De Berardis, Giampaolo Perna, Marco Solmi, Nicola Veronese, Laura Orsolini, Elisabetta Filomena Buonaguro, Felice Iasevoli, Cristiano André Köhler, André Ferrer Carvalho, Andrea de Bartolomei. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed research international. vol 2017. 2018-03-09. PMID:28573138. |
lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. |
2018-03-09 |
2023-08-13 |
Not clear |
| Michele Fornaro, Domenico De Berardis, Giampaolo Perna, Marco Solmi, Nicola Veronese, Laura Orsolini, Elisabetta Filomena Buonaguro, Felice Iasevoli, Cristiano André Köhler, André Ferrer Carvalho, Andrea de Bartolomei. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed research international. vol 2017. 2018-03-09. PMID:28573138. |
a burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its food and drug administration extended approval in 2013. |
2018-03-09 |
2023-08-13 |
Not clear |
| Melissa P DelBello, Robert Goldman, Debra Phillips, Ling Deng, Josephine Cucchiaro, Antony Loebe. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 56. issue 12. 2018-02-02. PMID:29173735. |
efficacy and safety of lurasidone in children and adolescents with bipolar i depression: a double-blind, placebo-controlled study. |
2018-02-02 |
2023-08-13 |
Not clear |
| Melissa P DelBello, Robert Goldman, Debra Phillips, Ling Deng, Josephine Cucchiaro, Antony Loebe. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 56. issue 12. 2018-02-02. PMID:29173735. |
to evaluate the efficacy and safety of lurasidone in children and adolescents with bipolar depression. |
2018-02-02 |
2023-08-13 |
Not clear |
| Nicholas A Keks, Judy Hope, David Castl. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression? Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 24. issue 3. 2018-01-26. PMID:27036122. |
lurasidone: an antipsychotic with antidepressant effects in bipolar depression? |
2018-01-26 |
2023-08-13 |
Not clear |
| Nicholas A Keks, Judy Hope, David Castl. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression? Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 24. issue 3. 2018-01-26. PMID:27036122. |
lurasidone is a new serotonin-dopamine antagonist atypical antipsychotic which also appears to be effective in bipolar depression. |
2018-01-26 |
2023-08-13 |
Not clear |
| Terence A Ketter, Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro, Antony Loebe. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depression and anxiety. vol 33. issue 5. 2018-01-04. PMID:26918425. |
the aim of this study was to evaluate the safety and tolerability of 6 months of open-label, uncontrolled extension treatment with lurasidone in patients with a diagnosis of bipolar depression who completed 6 weeks of acute treatment. |
2018-01-04 |
2023-08-13 |
Not clear |
| William M Greenberg, Leslie Citrom. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clinical pharmacokinetics. vol 56. issue 5. 2017-11-27. PMID:27722855. |
lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the us, canada, the eu, switzerland, and australia, and also for bipolar depression in the us and canada. |
2017-11-27 |
2023-08-13 |
Not clear |
| Trisha Suppes, Hans Kroger, Andrei Pikalov, Antony Loebe. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of psychiatric research. vol 78. 2017-08-29. PMID:27089521. |
lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. |
2017-08-29 |
2023-08-13 |
Not clear |